Two-Year Results from Pfizer's Xeljanz (Tofacitinib Citrate) ORAL Start Study Published
Pfizer Inc. has announced the publication of two-year results from the Oral Start study in the 19 June issue of The New England Journal of Medicine. ORAL Start is a 24-month Phase III study in patients with moderately to severely active rheumatoid arthritis (RA) who had not previously received methotrexate. The study showed that Xeljanz (tofacitinib citrate) 5 mg and 10 mg twice daily, as monotherapy (for example, taken without methotrexate), inhibited the progression of structural damage and reduced the signs and symptoms of RA, and was statistically significantly superior to methotrexate on these measures at Month 6 (primary endpoint) and at all measured time points up to 24 months. Xeljanz is not indicated in patients who had not previously received methotrexate. The safety profile of Xeljanz in the Oral Start study was consistent with that seen previously in the clinical development programme.
In the US, Xeljanz 5 mg tablets are indicated for the treatment of adults with moderately to severely active RA who have had an inadequate response or intolerance to methotrexate. Xeljanz may be used alone or in combination with methotrexate or other non-biologic, disease-modifying antirheumatic drugs (DMARDs). Use of Xeljanz in combination with biologic DMARDs or potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended. The recommended dose is a 5 mg pill taken twice daily.
"This study showed that Xeljanz taken by itself was statistically significantly superior to methotrexate in measures of clinical, radiographic and functional efficacy RA outcomes, and these results were sustained over 2 years," said lead investigator Roy M. Fleischmann, MD, professor, Metroplex Clinical Research Center, Dallas, Texas. "These results also add to the information on the efficacy and safety of Xeljanz as monotherapy."
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance